Novo Nordisk A/S (NVO) Company Profile
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.
News about NVO
Retirement at 40? Only if you can save this much
We're looking at a new dust-up in the retirement universe. What, exactly, is a reasonable age for retiring? Is 70 the new 65? Or is 35 the magic number? TV personality Suze Orman says don't dream about retiring a minute before you hit 70, while ...Read More>>>
ENI (ENI) Given a €15.00 Price Target by JPMorgan Chase & Co. Analysts
JPMorgan Chase & Co. set a €15.00 ($17.44) price objective on ENI (ETR:ENI) in a report published on Thursday morning. The firm currently has a sell rating on the stock. A number of other research firms have also recently weighed in on ENI...Read More>>>
Is the Marijuana Market Opportunity Legit?
Marijuana is one of the most exciting emerging industries for investors right now, but a lot of that excitement could be misplaced. The potential to profit from marijuana stocks will depend significantly upon cooperative governments and willing consu...Read More>>>
Analysts Expect Safe Bulkers, Inc. (SB) Will Post Earnings of $0.05 Per Share
Equities analysts expect Safe Bulkers, Inc. (NYSE:SB) to post $0.05 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Safe Bulkers’ earnings, with estimates ranging from $0.04 to ...Read More>>>
Redfin: An Integrated Full-Service Real Estate Competitor
With Redfin's (NASDAQ:RDFN) stock price in a downward spiral, currently almost back to its original IPO price, it got me interested in researching the company. I'm a licensed real estate agent in California and work full-time in real estate. At first...Read More>>>